These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 17116852

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Hand-foot and stump syndrome to sorafenib.
    Lai SE, Kuzel T, Lacouture ME.
    J Clin Oncol; 2007 Jan 20; 25(3):341-3. PubMed ID: 17235051
    [No Abstract] [Full Text] [Related]

  • 4. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M.
    J Clin Oncol; 2009 Sep 10; 27(26):4274-80. PubMed ID: 19652055
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
    Diamantis ML, Chon SY.
    J Drugs Dermatol; 2010 Feb 10; 9(2):169-71. PubMed ID: 20214183
    [Abstract] [Full Text] [Related]

  • 7. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J, Escudier B, Wechsler J, Spatz A, Robert C.
    Arch Dermatol; 2008 Jul 10; 144(7):886-92. PubMed ID: 18645140
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib-induced palmoplantar hyperkeratosis.
    Lountzis NI, Maroon MS.
    J Drugs Dermatol; 2008 Jun 10; 7(6):588-9. PubMed ID: 18561593
    [Abstract] [Full Text] [Related]

  • 9. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
    Hütten M, Lassay L, Sachs B, Deutz P, Mertens R, Baron JM, Merk HF, Ott H.
    Pediatr Dermatol; 2009 Jun 10; 26(3):349-50. PubMed ID: 19706105
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib: atypical cutaneous side effects.
    Richetta AG, Maiani E, Carboni V, Carlomagno V, Cimillo M, Mattozzi C, Calvieri S.
    Eur J Dermatol; 2007 Jun 10; 17(6):549-50. PubMed ID: 17951148
    [No Abstract] [Full Text] [Related]

  • 11. [Palmoplantar cutaneous reaction to sorafenib].
    Echeverría B, Llombart B, Botella-Estrada R, Guillén C.
    Actas Dermosifiliogr; 2009 Oct 10; 100(8):736-7. PubMed ID: 19775561
    [No Abstract] [Full Text] [Related]

  • 12. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW.
    Br J Dermatol; 2008 Mar 10; 158(3):592-6. PubMed ID: 18070211
    [Abstract] [Full Text] [Related]

  • 13. Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
    Lopez V, Pinazo I, Marti N, Monteagudo C, Jorda E.
    J Eur Acad Dermatol Venereol; 2009 Aug 10; 23(8):959-60. PubMed ID: 18785888
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
    Raymond AK, Puri PK, Selim MA, Tyler DS, Nelson KC.
    Arch Dermatol; 2010 Dec 10; 146(12):1438-9. PubMed ID: 21173337
    [No Abstract] [Full Text] [Related]

  • 16. Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report.
    Guillemois S, Patsouris A, Peyraga G, Chassain K, Le Corre Y, Campone M, Augereau P.
    Clin Breast Cancer; 2018 Oct 10; 18(5):e755-e758. PubMed ID: 30120047
    [No Abstract] [Full Text] [Related]

  • 17. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
    Eng FC, Easson AM, Szentgyorgyi E, Knox JJ.
    Eur J Surg Oncol; 2009 Feb 10; 35(2):219-21. PubMed ID: 17976949
    [No Abstract] [Full Text] [Related]

  • 18. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND, Ayer M, Küçükkaya RD, Alpay N, Mete O, Yenerel MN, Yavuz AS, Nalçaci M.
    Jpn J Clin Oncol; 2007 Sep 10; 37(9):704-7. PubMed ID: 17709605
    [Abstract] [Full Text] [Related]

  • 19. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
    Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L, Gianni L.
    Anticancer Drugs; 2009 Aug 10; 20(7):616-24. PubMed ID: 19739318
    [Abstract] [Full Text] [Related]

  • 20. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C, Müezzinoğlu T, Ermertcan AT, Kayhan TC, Temeltaş G, Oztürkcan S, Temiz P.
    Cutan Ocul Toxicol; 2009 Aug 10; 28(2):90-2. PubMed ID: 19514932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.